Hyperleptinemia May Protect From Cardio-Vascular Complications: A Small Georgian Study by Zerekidze, Tamar et al.
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Dec 15; 2(4):595-600.                                                                                                                                                                         595 
 
Open Access Macedonian Journal of Medical Sciences. 2014 Dec 15; 2(4):595-600. 
http://dx.doi.org/10.3889/oamjms.2014.106 
Clinical Science 
 
 
 
 
Hyperleptinemia May Protect From Cardio-Vascular 
Complications: A Small Georgian Study 
 
 
Tamar Zerekidze
1*
, Shota Janjgava
2
, Ketevan Asatiani
2
, Elene Giorgadze
2
 
 
1
Tbilisi State University, Department of Endocrinology, Tbilisi 0140, Georgia; 
2
National Institute of Endocrinology, Metabolic 
Disorders, Tbilisi 0159, Georgia 
 
 
 
Citation: Zerekidze T, Janjgava S, Asatiani K, Giorgadze 
E. Hyperleptinemia May Protect From Cardio-Vascular 
Complications: A Small Georgian Study. OA Maced J Med 
Sci. 2014 Dec 15; 2(4):595-600. 
http://dx.doi.org/10.3889/oamjms.2014.106 
Key words: Leptin; Anthropometric parameters; Body 
composition; Cardio-vascular risk factors; Lipid panel. 
*
Correspondence: Dr. Tamar Zerekidze. Tbilisi State 
University, Department of Endocrinology, Lubliana str 2/6, 
Tbilisi 0159, Georgia. E-Mail: t_zerekidze@yahoo.com 
Received: 18-Sep-2014; Revised: 20-Oct-2014; 
Accepted: 24-Oct-2014; Online first: 04-Nov-2014 
Copyright: © 2014 Tamar Zerekidze, Shota Janjgava, 
Ketevan Asatiani, Elene Giorgadze. This is an open 
access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, 
provided the original author and source are credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
List of Abbreviations: BMC – Bone Mineral Component; 
BMI – Body Mass Index; DXE – Duel Energy X-ray 
absorptiometry; HDL-C – High Density Lipoprotein 
Cholesterol; HOMA-IR – Homeostatic Model Assessment 
of Insulin Resistance; LDL-C – Low Density Lipoprotein 
Cholesterol; TG – Triglycerides; Total Chol – Total 
Cholesterol; WC – Waist Circumference. 
 
 
 
 
 
 
 
Abstract  
BACKGROUND AND AIM: Leptin was assessed to play a coordinating role in obesity and its 
cardio-vascular complications, however the findings are conflicting and further clinical investigation 
is required. The aim of the present study was to evaluate the association of serum leptin with 
cardio-vascular risk factors in different body mass index and age groups.  
MATERIALS AND METHODS:  One hundred and forty nine female patients were enrolled in the 
study and divided into groups according to body mass index (BMI) and age. Following 
measurements were carried out: height, weight, BMI, waist circumference, blood pressure. Venous 
blood sample was obtained for plasma leptin, insulin, glucose and lipid profile analysis. Insulin 
resistance index was calculated for each patient. Body fat distribution was measured using Dual 
energy X-ray Absorbtiometry.  
RESULTS: The lowest leptin concentration was observed in overweight patients, the highest 
concentration was seen in obese patients. The difference between leptin levels were not observed 
in age groups. Leptin positively correlated with high density lipoprotein cholesterol levels in obese 
and elder patients. 
CONCLUSION: Leptin might act as a preventive measure for cardiovascular complications only in 
the presence of sufficient amount of fat mass. Further studies are warranted in order to support 
these results. 
 
 
 
 
 
Introduction 
 
Obesity is an increasingly prevalent metabolic 
disorder affecting developed and developing 
countries. It contributes to abnormality in glucose 
metabolism, lipid profile and blood pressure [1].  
The etiology of obesity is multifactorial, with 
the underlying causes including both lifestyle and 
genetic factors [2]. Obesity has long been considered 
as a behavioral and social disorder. The discovery of 
leptin in 1994 brought a complete revolution to the 
concept of obesity [3]. Leptin is a 16 kDa protein 
hormone and a cytokine, which is mainly synthesized 
and secreted by subcutaneous white adipose cells; its 
serum levels are directly proportional to the adipocyte 
mass [4]. Leptin stimulates energy expenditure and 
inhibits appetite via the hypothalamus [5]. The 
importance of leptin was clearly demonstrated by 
individuals with congenital leptin deficiency. However, 
congenital leptin deficiency is a rare human genetic 
syndrome [6]. At present, the obese population is not 
characterized by leptin deficiency, but by 
hyperleptinemia, which is indicative of a leptin-
resistant state [7].   
Several experimental studies have shown that 
increased leptin may directly or indirectly exert 
multiple actions at the cardio-vascular level. Number 
of investigations has detected a significant association 
between circulating plasma leptin with insulin 
resistance and inflammatory markers, suggesting a 
possible role of leptin in development of 
cardiovascular disease. Some animal studies have 
revealed that specific high density lipoprotein 
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cholesterol (HDL-C) catabolic pathways are likely 
regulated by obesity and/or by leptin signaling; 
furthermore, serum leptin production in humans has 
been found to be related to arterial hypertension. 
These observations led to the hypothesis that leptin 
may play a coordinating role in obesity and may lead 
to cardio-vascular complications [8 – 12]. In a study 
conducted by Adami at al., the higher leptin 
concentration was associated with the higher serum 
HDL-C levels and lower cardiovascular risk [13]. 
Based on these conflicting findings, further clinical 
investigation is required to resolve this issue. 
Statistical data demonstrate a remarkable growth in 
the obesity rates among Georgian population. The 
aim of the present study is to investigate the role of 
leptin in pathophysiological consequences of human 
obesity, including cardiovascular disease. Specifically, 
we assessed the relationship between serum leptin 
concentration and cardiovascular risk parameters in 
the overweighted and obese patients.  
 
 
Materials and Methods 
 
Subject characteristics 
Subject enrolment was conducted during one 
year (2010), at the National Institute of Endocrinology 
Clinic (Tbilisi, Georgia). The study was approved by 
the ethical committee of the National Institute of 
Endocrinology according to the declaration of Helsinki. 
Inclusion criteria were: females, age from 20 
to 70, informed written consent for participation in the 
study. Exclusion criteria were: alcohol or drug abuse, 
pregnancy, nursing (lactation), cardiac, respiratory, 
inflammatory or other endocrine diseases. Overall 149 
female subjects were enrolled in the study.  
In order to assess the relationship between 
serum leptin concentration and cardiovascular risk 
parameters, the leptin levels were determined in 
whole targeted population. Leptin levels were 
separately assessed in three different groups of 
weight and two different groups of age categories. 
The groups were defined as follows:  
Weight category (according to body mass 
index – BMI): Group I – normal weight; Group II – 
overweight patients; and Group III – obese patients. 
Age category: Group I – 20-40 year old 
patients; and Group II – 40-70 year old patients.   
Following measurements were carried out for 
all participants: assessment of height, weight, body 
mass index (BMI), waist circumference and blood 
pressure. Venous blood samples were obtained to 
measure plasma levels of leptin, insulin and glucose, 
as well as for lipid profile analysis (including total 
cholesterol, triglycerides, high density lipoprotein 
cholesterol and low density lipoprotein cholesterol). 
Insulin resistance index (HOMA IR) was calculated for 
each patient. Body fat distribution was measured 
using Dual energy X-ray Absorbtiometry (DXA; GE 
Healthcare; Lunar Prodigy Primo). 
 
Anthropometric measurements 
Height and weight were evaluated in all 
subjects. Body mass index (BMI) was calculated as 
weight in kilograms (kg) divided by square of height in 
meters (m²) and was expressed in kg/m². According to 
the world health organisation classification normal 
weight was defined as the BMI from 18.5 to 24.9 
kg/m², overweight was specified as BMI from 25 to 
29.9 kg/m² and obesity was defined as BMI > 30 
kg/m² [14].   
Waist circumference (WC) was measured as 
a midway between the iliac crest and the lower margin 
of the 12
th
 rib, and was expressed in centimetres.  
 
Blood Pressure 
Unit of pressure was expressed in millimetres 
of mercury (mmHg). Blood pressure was measured 
after 5 - minute rest on the right arm, using a manual 
sphygmomanometer. After 2 minute interval the 
pressure was measured on the left arm. The arm with 
the highest blood pressure was used for another two 
measurements with 2 - minute intervals. The average 
value after 3 measurements on the same arm was 
used in analysis. All the measurements were done by 
a single operator (T. Z). 
 
Biochemical Measurements 
After a 10 – 12 - hour fasting period, venous 
blood samples were obtained between 09:00 a.m. and 
11:00 a.m., and stored at 4ºC. Blood plasma glucose 
and serum lipid profile [total cholesterol, triglycerides 
(TG), high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C)] were 
estimated using a glucose oxidase-peroxidase and 
enzymatic methods, respectively. Leptin and insulin 
levels were determined by sandwich enzyme-linked 
immunosorbent assay (ELISA). Leptin was measured 
in nanograms per milliliter (ng/mL), and insulin was 
measured in milliunits per liter (mU/L). Insulin 
resistance index – HOMA-IR was calculated 
according to the formula: fasting insulin (mU/L) X 
fasting glucose (mmol/l) / 22.5 [15].   
 
Body Composition  
Body composition was assessed by dual-
energy X-ray absorptiometry (DXA; GE Healthcare; 
Lunar Prodigy Primo). Measurements were conducted 
in the morning, while the subjects were still in fasting 
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regiment. We performed a whole-body DXA scan and 
analysis, which generates estimates of fat-free mass, 
fat mass and bone mineral content in each separate 
body regions – arms, legs, trunk, android and gynoid. 
 
Statistical analysis 
The data were presented as mean ± standard 
deviation (SD). Differences between groups were 
measured using student’s t-test. Pearson’s correlation 
coefficient (r) was calculated to determine the 
relationship between study parameters. P-value < 
0.05 was considered statistically significant for all 
analyses. Statistical analyses were performed using 
the SPSS 15.0 software package (SPSS, Inc., 
Chicago, IL). 
 
 
Results 
 
One hundred and forty nine female patients 
had been involved in research. Patients were 
subdivided according to BMI.  
Group I consisted of subjects with normal 
weight (BMI 18.5 - 24.9) – 19 individuals (12.7%); 
group II was formed by 41 overweight (BMI 25 - 29.9) 
individuals (27.52%); group III included 89 obese (BMI 
30 - 44.9) patients (59.7%).  
Correlations between leptin and assessed 
parameters (weight, height, BMI, waist circumference, 
systolic and diastolic blood pressure, lipid profile, 
fasting glucose, insulin and insulin resistance index, 
total fat distribution and fat distribution in different 
regions of the body) were evaluated in the whole 
examined population, as well as among the groups 
divided according to BMI and age. The mean values 
and standard deviation of the evaluated parameters 
are given in Table 1. 
In the whole population group, leptin 
concentrations correlated with weight, BMI, waist 
circumference, systolic, diastolic arterial blood 
pressure, HDL-C, LDL-C, fasting glucose, HOMA-IR; 
Body composition parameters (fat tissue %, and 
distribution). Statistically significant correlations were 
estimated between leptin concentrations and weight, 
BMI, waist circumference, blood pressure, fat tissue 
mass%, fat tissue distribution:  arms, legs, trunk, 
abdomen, android, gynoid (Fig. 1).  
 
 
Figure 1: Positive correlations of leptin in total population. The 
figure shows correlation of leptin in total study population with BMI 
(r = 0.53, p < 0.001), weight (r = 0.49, p < 0.001), WC (r = 0.47, p < 
0.001), total body fat% (r = 0.55, p < 0.001), systolic and diastolic 
blood pressure (r = 0.36, p < 0.001 and r = 0.3, p < 0.001, 
respectively), HDL-C and LDL-C (r = 0.18, p < 0.05 and r = 0.23, p 
< 0.01, respectively).  
 
Correlation was changed in the examined 
sub-groups: in normal weight (I group) individuals 
leptin levels positively correlated with systolic blood 
pressure, fasting glucose level, and fat mass % (Fig. 
2). 
In group II individuals leptin levels positively 
correlated with BMI and LDL-C (Fig. 3). 
 
Table 1: Mean values and standard deviation of the evaluated parameters. 
Study 
Components 
Mean ±SD 
Total Study 
Population 
n = 149 
Groups Divided by BMI Groups Divided by Age 
Normal-Weight 
n = 19 
Overweight 
n = 41 
Obese 
n = 89 
20 - 40 Year 
n = 119 
40 - 70 Year 
n = 30 
Age (year) 31.58 ± 10.37 25.32 ± 5.49 29 ± 7.48 34.11 ±  11.45 27.34 ± 6 48.43 ± 5.86 
Weight (kg) 87.78 ± 17.2 63.51 ± 6.84 77.62 ± 6.15 97.65 ± 14.04 85.59 ± 16.99 96.48 ± 15.44 
Height (cm) 165.9 ± 5.7 166.21 ± 5.93 167.68 ± 5.18 165.01 ± 5.74 166.11 ± 5.58 165.07 ± 6.19 
BMI (kg/m2) 31.86 ± 6.39 22.57 ± 1.39 27.5 ± 1.52 35.86 ± 4.86 30.98 ± 6.25 35.37 ± 5.80 
WC (cm) 102.52 ± 18.31 75.74 ± 8.25 92.78 ± 8.65 112.72 ± 14.54 100.13 ± 18.15 111.97 ± 15.97 
SBP (mmHg) 124.39 ± 12.67 113.68 ± 5.74 117.93 ± 8.73 129.65 ± 12.5 121.59 ± 10.61 135.5 ± 14.16 
DBP (mmHg) 81.48 ± 10.78 71.84 ± 6.5 76.32 ± 8.28 85.91 ± 10.16 79.33 ± 9.61 90 ± 11.06 
Leptin (ng/mL) 67.76 ± 31.71 67.74 ± 29.35 54.38 ± 27.89 80.84 ± 26.05 65.83 ± 31.49 75.43 ± 31.95 
Insulin (mU/L) 13.87 ± 7.83 9.51 ± 4.54 12.48 ± 4.67 15.09 ± 8.91 13.39 ± 7.45 15.72 ± 9.14 
Glucose (mg/dl) 93.47 ± 10.10 89 ± 7.22 93.80 ± 8.82 94.27 ± 10.97 92.34 ± 9.04 97.93 ± 12.73 
HOMA-IR 3.27 ± 2.2 2.07 ± 0.99 2.9 ± 1.13 3.6 ± 2.56 3.05 ± 1.76 4.1 ± 3.34 
Total Chol. (mg/dl) 206.14 ± 20.6 199.57 ± 15.29 200.88 ± 14.98 209.97 ± 22.95 203.04 ± 18.18 218.47 ± 24.98 
TG (mg/dl) 195.42  ± 22.75 188.13 ± 18.68 190.47 ± 25.31 199.25 ± 21.68 192.73 ± 21.77 206.08 ± 23.80 
HDL-C (mg/dl) 69.89 ± 4.59 70.52 ± 4.49 69.49 ± 4.55 69.93 ± 4.66 69.92 ± 4.69 69.75 ± 4.2 
LDL-C (mg/dl) 105.17 ± 10.64 101.74 ± 10.76 102.67 ± 11.92 107.08 ± 9.64 103.66 ± 10.79 111.1 ± 7.66 
Fat % 47.34 ± 6.62 37.95 ± 5.86 43.57 ± 4.58 51.12 ± 4.12 47 ± 6.9 48.65 ± 5.3 
Fat (kg) 39.97 ± 11.93 22.90 ± 4.8 32.01 ± 5.09 47.37 ± 8.66 38.78 ± 12.07 44.65 ± 10.25 
Lean (kg) 42.97 ± 6.35 37.15 ± 4.47 41.18 ± 3.43 45.06 ± 6.73 42.16 ± 6.17 46.17 ± 6.13 
BMC (kg) 2.91 ± 0.41 2.46 ± 0.44 2.90 ± 0.34 3.02 ± 0.37 2.90 ± 0.42 2.95 ± 0.36 
Arms (kg) 43.85 ± 7.38 34.51 ± 6.97 39.9 ± 5.27 47.71 ± 5.27 43.17 ± 7.45 46.54 ± 6.57 
Legs (kg) 50.12 ± 7.41 41.52 ± 7.55 46.15 ± 5.41 53.83 ± 5.48 50.02 ± 7.76 50.54 ± 5.94 
Trunk (kg) 48.24 ± 6.88 38.29 ± 5.88 44.74 ± 5.33 52.01 ± 4.25 47.83 ± 7.08 49.85 ± 5.87 
Android (kg) 52.21 ± 7.62 41.43 ± 7.35 48.33 ± 6.11 56.35 ± 4.48 51.61 ± 7.67 54.61 ± 7.06 
Gynoid (kg) 53.11 ± 5.86 46.63 ± 5.46 50.14 ± 4.37 55.90 ± 4.69 53.21 ± 6.09 52.73 ± 4.97 
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Figure 2: Positive correlations of leptin in a group of patients with 
normal weight. In normal weight group leptin positively correlation 
with systolic blood pressure (r = 0.34, p < 0.01), fasting plasma 
glucose (r = 0.2, p = 0.005), total body fat% (r = 0.22, p = 0.004), fat 
amount in trunk (r = 0.28, p = 0.02) and android fat (r = 0.2, p = 
0.05).  
 
In group III leptin levels positively correlated 
with BMI and HDL-C, fat mass %, fat distribution in 
arms, trunk and android regions (Fig. 4). 
 
Figure 3: Positive correlations of leptin in overweight patients. In 
overweight study group leptin positively correlated with BMI (r = 
0.28, p = 0.05) and LDL-C (r = 0.37, p = 0.02).   
 
Analysis revealed lowest leptin concentrations 
in group II, and highest leptin concentrations in group 
III. The leptin concentration diversity had the highest 
statistical significance among the groups. 
 
Figure 4: Positive correlations of leptin in obese patients. The 
correlation of leptin was positive with BMI (r = 0.22, p = 0.04), HDL-
C (r = 0.27, p = 0.01), total body fat% (r = 0.25, p = 0.01), fat 
amount in arms (r = 0.33, p < 0.001), trunk (r = 0.22, p = 0.03) and 
android fat (r = 0.31, p = 0.003) in the study group consisted of 
obese patients.  
According to the age division the group of 
subjects from 20 to 40 years consisted of 119 women 
and the group of subjects from 40 to 70 years 
consisted of 30 women. 
Comparison of leptin levels in two different 
age groups revealed that older age was associated 
with higher leptin levels. However, according to the 
regression analysis, age is not an important 
determinant of leptin, when adjusted with the weight. 
Analysis also demonstrated that age positively 
correlated with weight. 
Among the 20 - 40 year old age group, leptin 
concentration positively correlated with weight, BMI, 
waist circumference, systolic and diastolic blood 
pressure, fasting glucose level, LDL-C level, total fat 
mass, BMD, fat tissue distribution: arms, legs, trunk, 
android and gynoid (Fig. 5).  
 
 
Figure 5: Positive correlations of leptin in a group of patients aged 
20-40 years. In the study group consisted of patients aged 20-40 
years leptin showed positive correlation with weight (r = 0.48, 
p<0.001), BMI (r = 0.53, p < 0.001), WC (r = 0.45, p < 0.001), 
systolic and diastolic blood pressure (r = 0.37, p < 0.001 and 
r=0.33, p < 0.001, respectively), fasting plasma glucose (r = 0.24, 
p=0.01), LDL-C (r = 0.21, p = 0.02) and total body fat% (r = 0.56, 
p<0.001). 
 
In 40 - 70 year old patents, leptin positively 
correlated with weight, B.M.I., waist circumference, 
HDL-C, Total fat mass and fat tissue distribution: 
arms, legs, trunk, android, and gynoid (Fig. 6).  
 
 
 
Figure 6: Positive correlations of leptin in a group of patients aged 
40-70 years. In the group of patients aged 40-70 leptin positively 
correlated with weight (r=0.47, p=0.01), BMI (r=0.48, p=0.01), WC 
(r=0.49, p=0.01), HDL-C (r=0.53, p<0.001) and total body fat % 
(r=0.48, p=0.01).  
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Discussion 
 
The aim of the present study was to assess 
the association of serum leptin with cardio-vascular 
risk parameters and to compare the levels of the 
investigated factors among the patient groups divided 
according to BMI and age. 
Based on the obtained data, the main 
conclusions are the following: 1. Leptin concentration 
was highest in the obese group; 2. Leptin levels 
increase with the age; 3. Leptin expression positively 
correlates with HDL-C, in total population and in the 
groups  of obese and 40 - 70 year old subjects; 4. The 
strongest positive correlation was detected between 
leptin and body fat mass in every region of the body, 
mostly in  the total study population and in the group 
of obese subjects. 
Levels of leptin increased with the age, which 
is consistent with previous reports by Andreasson et 
al. and others, and can be explained by the increase 
in BMI [16].
 
 
Our study revealed a correlation between 
serum leptin and anthropometric characteristics in the 
total population, but when the population was divided 
into groups (according to BMI), the correlation was 
changed and positive correlation was seen only in the 
groups of overweight and obese subjects. Our results 
are in line with Liuzzi A et al. and Adami GF et al., 
who also showed that leptin appeared to positively 
correlate with BMI in all age groups [13, 17]. In our 
study the correlation of leptin with BMI was observed 
in both age groups. Similar results, regarding highly 
significant correlation between serum leptin and BMI, 
were demonstrated in the study performed by Al-
Shoumer KA et al [18]. Concerning the correlation of 
leptin with WC had been observed only in total study 
population and also in both age groups (Fig-s. 1, 5, 6).  
Along with the assessment of body weight 
and BMI characterizing the state of obesity of an 
individual, we also evaluated fatty tissue, fat free 
mass and BMC. A detailed evaluation of these body 
composition components is important.  
In the present study, leptin showed most 
significant and positive correlation with body fat 
distribution. Correlation of serum leptin and lean 
mass, as well as BMC, was not detected (Fig. 2). 
Correlation of leptin with fat mass and fat distribution 
in regions was positive in total study population. In 
overweight patients the correlation was not observed. 
In patients with normal weight and obesity leptin 
correlated with total fat mass and fat mass in trunk 
and abdomen (Fig. 3). Our data are in line with the 
study conducted by Garcia-Lorda P et al., although 
their study was conducted only on females [19].  
The present study confirms the strong 
association of total adiposity with leptin. Our results 
indicate that total percentage of fat had the same 
correlation with leptin concentration as total body fat 
mass.  
The association of leptin with blood pressure 
was seen in the total population and 20 - 40 year old 
subjects. Obesity is associated with risk of high blood 
pressure (Fig. 4). Several studies confirm that leptin 
increases the activity of sympathetic nervous system, 
though contribution to elevated blood pressure. 
Differences in leptin transport across the blood–brain 
barrier may exist between men and women [20]. As a 
result, women's sympathetic nervous system may 
have a weaker response to leptin than men's. If this is 
the case, women could be more protected against 
leptin-induced high blood pressure, as compared to 
men [21]. In the study, conducted by Adreasson et al., 
women showed lower associations between high 
levels of leptin and CVD risk factors [16]. 
Our results are in agreement with the results 
obtained in the study conducted by Alvarez-Aguilar C 
et al. They suggest that hyperleptinemia has a direct 
role in the physiopathologic mechanism of obesity-
associated high blood pressure [22].  
Our study shows that leptin levels correlate 
with fasting glucose and HOMA-IR, only in the total 
study population. Leptin positively correlated with 
fasting glucose in 20 - 40 year old patients.  
Low and high-density lipoproteins are major 
determinants of cholesterol transporter in human 
plasma. The pre-atherogenic LDL-C and HDL-C are 
high biological predictors of cardiovascular disease. In 
our study leptin positively correlated with HDL-C in 
total study population and in the group of patients with 
obesity (Fig. 5). Similar results are shown in Adami 
GF al., where leptin appeared to positively correlate 
with HDL-C. In line with the Adami et al. results, our 
data showed that higher the leptin concentration 
associated with higher serum HDL-C level [13]. HDL-
C is considered as the single major factor for 
predicting the risk of atherosclerosis and coronary 
artery disease [23]. A rise in HDL-C reduces the 
incidence of coronary artery disease. The positive 
relationship between leptin and HDL-C in obese and 
40 - 70 year old patients shows that increased leptin 
in obese and elder patients increase HDL-C, thus 
decreasing the incidence of coronary disease in these 
patients. Leptin showed positive correlation with both, 
LDL-C and HDL-C, in total study population. In 
patients with normal weight leptin had no correlation 
with either of the cholesterol transporters. In 
overweight and 20 - 40 year old patients the positive 
correlation was seen only with LDL-C (Fig. 5). This 
phenomenon could be explained by theory that 
increased levels of leptin might act as protective 
mechanism against cardio-vascular disease in obese 
and aged patients. Our results are in conflict with 
major studies done in these filed. According to the 
results of some studies, leptin may protect from 
cardiovascular complications, most likely due to its 
association with peripheral, but not central body fat 
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distribution [12, 24].
 
Furthermore, several studies 
detected a complete lack of relationship between 
serum leptin and HDL-cholesterol concentration in 
normal weight individuals [25 – 27]. We hypothesize 
that leptin might act as a preventive measure for 
cardiovascular complications only in the presence of 
sufficient amount of fat mass. However, further 
investigation is needed in order to support these 
results.  
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